Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia

Blood

Volumn 90, Issue 12, 1997, Pages 4918-4923

  Ben Yehuda, Dina ^a   Krichevsky, Svetlana ^b   Rachmilewitz, Eliezer A ^b   Avraham, Ayelet ^b   Palumbo, Giuseppe A ^b   Frassoni, Francesco ^b   Sahar, Dvora ^b   Rosenbaum, Hanna ^b   Paltiel, Ora ^b   Zion, Michal ^b   Ben Neriah, Yinon ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DNA; HYDROXYUREA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0031454221     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.12.4918.4918_4918_4923     Document Type: Article

References (35)

1. Silver RT: Chronic myeloid leukemia. A perspective of the clinical and biologic issues of the chronic phase. Hematol Oncol Clin North Am 4:319, 1990
2. Allan NC, Richards SM, Shepherd PC: UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345:1392, 1995
3. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C, and the Italian Cooperative CML Study Group: Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789, 1984
4. Italian Cooperative Study Group on CML: Prospective confirmation of a prognostic classification for Ph-positive CML. Br J Haematol 69:463, 1988
5. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB: Proposal for simple staging system in chronic myelogenous leukemia. Am J Med 88:1, 1990
6. Wareham NJ, Johnson SA, Goldman JM: Relationship of the duration of chronic phase in CML to the need for treatment during the first year after diagnosis. Cancer Chemother Pharmacol 8:205, 1982
7. Sawyers CL: Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia. Leuk Lymphoma 11:101, 1993 (suppl 2)
8. Mitelman F: The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 11:11, 1993 (suppl 1)
9. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990
10. Ahuja H, Bar-Eli M, Arlin Z, Advani S, Alien SL, Goldman J, Snyder D, Foti A Cline M: The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 87:2042, 1991
11. Neubauer A, He M, Schmidt CA, Huhn D, Liu ET: Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: Analysis by polymerase chain reaction based techniques. Leukemia 7:593, 1993
12. Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM: Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 14:196, 1996
13. Blick M, Romero P, Talpaz M, Kurzrock R, Shtalrid M, Andersson B, Trujillo J, Berman M, Gutterman J: Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet 27:349, 1987
14. Ahuja HG, Jat PS, Foti A, Bar-Eli M, Cline MJ: Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 78:3259, 1991
15. Sill H, Goldman JM, Cross NC: Homozygous deletions of the p 16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013, 1995
16. Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, Melloul D, Ben-Neriah Y: Progressive de novo DNA methylation at the bcr/abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA 91:10722, 1994
17. Miyamura K, Barren AJ, Kodera Y, Saito H: Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: A review of recent results. Bone Marrow Transplant 14:201, 1994
18. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J: Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280, 1987
19. The Italian Cooperative Study Group on chronic myeloid leukemia: Interferon α2a as compared with conventional chemotherapy for treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994
20. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queiber W, Loffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griebhammer M, Bergmann L, Essers U, Flage C, Queiber U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Kabisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow PV, Prummer O, Thiele J, Buhr T, Carbonell F, Ansari H, and the German CML Study Group: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064, 1994
21. Hughes TP, Goldman JM: Chronic myeloid leukemia, in Hoffman R, (ed): Hematology, Basic Principles and Practice. New York, NY, Churchill Livingstone, 1995, p 1146
22. Bird AP: CpG-rich islands and the function of DNA methylation. Nature 321:209, 1986
23. Li E, Beard C, Forster AC, Bestor TH, Jaenisch R: DNA methylation, genomic imprinting, and mammalian development. Cold Spring Harb Symp Quant Biol 58:297, 1993
24. Ramsahoye BH, Davies CS, Mills KI: DNA methylation: Biology and significance. Blood Rev 10:249, 1996
25. Jones PA: DNA methylation errors and cancer. Cancer Res 56:2463, 1996
26. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B: Epigenetic changes may contribute to the formation of spontaneous regression of retinoblastoma. Hum Genet 83:155, 1989
27. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan D-SR, Gnarra JR, Linehan WM, Baylin SR: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700, 1994
28. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Jones PA: 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/ MTS1 in human cancers. Nat Med 1:686, 1995
29. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA: Methylation of the 5′ CpG island of the p16/CDKN2/MTS1 tumor suppressor genes in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531, 1995
30. Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte ON: The nuclear tyrosine kinase c-abl negatively regulates growth. Cell 77:121, 1994
31. Wen ST, Jackson PK and Van Etten RA: The cytostatic function of c-abl is controlled by multiple nuclear localization signals and requires the p53 and Rb suppressor gene products. EMBO J 15:1583, 1996
32. Malinen T, Palotie A, Pakkala S, Peltonen L, Ruutu T, Jansson SE: Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation. Blood 77:2435, 1991
33. Litz CE, McClure JS, Coad JE, Goldfarb AN, Brunning RD: Methylation status of the major breakpoint cluster region in Philadelphia chromosome negative leukemias. Leukemia 6:35, 1992
34. Mills KI, Sproul AM, Ogilvie D, Elvin P, Leibowitz D, Burnett AK: Amplification and sequencing of genomic breakpoints located within the M-bcr region by Vectorette-mediated polymerase chain reaction. Leukemia 6:481, 1992
35. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ: Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61:1441, 1988